Results 51 to 60 of about 704,437 (356)

Cross-World Comparatives for Modal Realists [PDF]

open access: yes, 2018
Divers (2014) argues that a Lewisian theory of modality which includes both counterpart theory and modal realism cannot account for the truth of certain intuitively true modal sentences involving cross-world comparatives.
Michels, Robert
core  

Molecular imaging predicts trastuzumab‐deruxtecan (T‐DXd) response in head and neck cancer xenograft models

open access: yesMolecular Oncology, EarlyView.
Trastuzumab‐deruxtecan, a HER2‐targeting antibody‐drug conjugate, shows promising antitumor activity in head and neck squamous cell carcinoma with low HER2 expression. In vitro and in vivo studies demonstrated dose‐dependent cell death and tumor growth reduction in low HER2‐expressing cell lines, which correlated with drug accumulation measured using a
Abdullah Bin Naveed   +8 more
wiley   +1 more source

External radiotherapy of thyroid cancer [PDF]

open access: yes, 2001
Differentiated thyroid cancer comprises papillary, mixed papillary-follicular and follicular adenocarcinomas. They are mostly hormone-sensitive and respond to thyroid-stimulating hormone (TSH) suppression. The standard treatment is total thyroidectomy. I-
Dühmke, Eckhart, Pollinger, B.
core   +1 more source

Association of high‐dose radioactive iodine therapy with PPM1D‐mutated clonal hematopoiesis in older individuals

open access: yesMolecular Oncology, EarlyView.
In thyroid cancer patients, high‐dose (≥7.4 GBq) radioactive iodine therapy (RAIT) was associated with a higher prevalence of clonal hematopoiesis (variant allele frequency >2%) in individuals aged ≥50 years (OR = 2.44). In silico analyses showed that truncating PPM1D mutations conferred a selective advantage under these conditions.
Jaeryuk Kim   +11 more
wiley   +1 more source

Age-related differences in primary central nervous system lymphomas based on the SEER database

open access: yesFrontiers in Medicine
ObjectiveThe aim of this study was to compare prognostic factors and survival outcomes in patients with primary central nervous system lymphoma (PCNSL).MethodsThe Surveillance, Epidemiology, and End Results (SEER) database was queried for patients ...
Tengjiao Lin   +9 more
doaj   +1 more source

Transarterial therapy: An evolving treatment modality of hepatocellular carcinoma

open access: yesThe Saudi Journal of Gastroenterology, 2014
Liver cancer is the fifth most common cancer in men, the seventh most common in women, and the third most common cause of death from cancer worldwide.
Khalid A Jazieh   +2 more
doaj   +1 more source

Unenhanced whole-body MRI versus PET-CT for the detection of prostate cancer metastases after primary treatment [PDF]

open access: yes, 2016
The aim of this study was to evaluate the accuracy of unenhanced whole-body MRI, including whole-body Diffusion Weighted Imaging (DWI), used as a diagnostic modality to detect  pathologic lymph nodes and skeletal metastases in patients with prostate ...
AL ANSARI, Najwa   +10 more
core  

The role of stereotactic radiosurgery in the multimodal management of growth hormone–secreting pituitary adenomas [PDF]

open access: yes, 2010
Growth hormone (GH)–secreting pituitary adenomas represent a common source of GH excess in patients with acromegaly. Whereas surgical extirpation of the culprit lesion is considered first-line treatment, as many as 19% of patients develop recurrent ...
Liu, Charles Y.   +2 more
core   +1 more source

Treatment modality drift [PDF]

open access: yesBritish Dental Journal, 2021
K G Varghese   +4 more
openaire   +3 more sources

Olaparib synergy screen reveals Exemestane induces replication stress in triple‐negative breast cancer

open access: yesMolecular Oncology, EarlyView.
Screening 166 FDA‐approved anticancer drugs identifies the aromatase inhibitor Exemestane as a synergistic partner of PARP inhibitor Olaparib in BRCA‐proficient triple‐negative breast cancer. Exemestane induces ROS‐mediated replication stress, enhancing DNA damage and apoptosis alongside Olaparib.
Nur Aininie Yusoh   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy